Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on Lipocine in a research report on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target for the company.

Lipocine Price Performance

NASDAQ LPCN opened at $4.89 on Thursday. The company’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $5.12. Lipocine has a 1 year low of $3.02 and a 1 year high of $11.79. The stock has a market capitalization of $26.15 million, a PE ratio of -6.43 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Lipocine will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC lifted its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the quarter. Renaissance Technologies LLC owned 0.48% of Lipocine worth $212,000 at the end of the most recent quarter. 9.11% of the stock is owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.